diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand. — Wikipedia
Clinical trial activity
22 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2004 (NCT00831311)
Timeline
Indications
Studied for
- Diphtheria · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Haemophilus Infections · Phase 3
- Haemophilus influenzae · Phase 3
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 3
- Hepatitis B · Phase 3
- HIV · Phase 3
- Poliomyelitis · Phase 3
- Safety · Phase 3
- Streptococcal Infections · Phase 3
- Tetanus · Phase 3
- Whooping Cough · Phase 3
Mechanism of action
- Diphtheria toxinImmunity, active
Diphtheria toxin immunity, active
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
- PoliovirusImmunity, active
Poliovirus immunity, active
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
- Haemophilus influenzaeImmunity, active
Haemophilus influenzae immunity, active
- Tetanus toxinImmunity, active
tetX immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHexavalent vaccine ↗
Also known as
- dtpw-hbv/hib
- dtwp-hepb-hib vaccine
- eutravac
- hexaxim
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05482282 | Phase 3 | Oct 31, 2022 | Government of Indonesia, PT Bio Farma |
| NCT04071379 | Phase 3 | Dec 20, 2019 | Government of Indonesia, PT Bio Farma |
| NCT02817451 | Phase 3 | Jul 14, 2016 | Sanofi, Sanofi-Aventis |
| NCT02610348 | N/A | Nov 1, 2015 | Sanofi, Sanofi-Aventis |
| NCT02447432 | Phase 3 | Jun 11, 2015 | GlaxoSmithKline |
| NCT02428491 | Phase 3 | Apr 1, 2015 | Government of Vietnam, Sanofi, Sanofi-Aventis |
| NCT02094833 | Phase 3 | Mar 1, 2014 | Sanofi, Sanofi-Aventis |
| NCT01948193 | Phase 3 | Feb 1, 2014 | Sanofi, Sanofi-Aventis |
| NCT01470287 | Phase 3 | Dec 1, 2011 | Novartis |
| NCT01444781 | Phase 3 | Sep 1, 2011 | Sanofi, Sanofi-Aventis |
| NCT01177722 | Phase 3 | Aug 1, 2010 | Sanofi |
| NCT01896739 | Phase 3 | Aug 1, 2009 | LG |
| NCT00831753 | Phase 3 | May 1, 2008 | Sanofi |
| NCT00654901 | Phase 3 | Mar 1, 2008 | Sanofi, Sanofi-Aventis |
| NCT00619502 | Phase 3 | Dec 1, 2007 | Sanofi |
| NCT00404651 | Phase 3 | Nov 1, 2006 | Sanofi |
| NCT00401531 | Phase 3 | Oct 1, 2006 | Sanofi |
| NCT00362336 | Phase 3 | Aug 1, 2006 | Sanofi |
| NCT00343889 | Phase 3 | Aug 1, 2006 | Sanofi |
| NCT00313911 | Phase 3 | Jul 1, 2006 | Sanofi |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 17 | 17 | 3 | 2004 |
| Sanofi-Aventis | For profit | 8 | 0 | 2 | 2006 |
| Government of Indonesia | Government | 2 | 0 | 1 | 2019 |
| PT Bio Farma | For profit | 2 | 2 | 1 | 2019 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2015 |
| Government of Vietnam | Government | 1 | 0 | 1 | 2015 |
| LG | For profit | 1 | 1 | 1 | 2009 |
| Novartis | For profit | 1 | 1 | 1 | 2011 |